UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~July~~September 2821, 2011

Commission File Number: 333-146744

CAPSALUS CORP.

(Exact Name of registrant as specified in charter)

Nevada

(State or other jurisdiction of incorporation or organization)

2675 Paces Ferry Road Suite 100

Atlanta, GA 30339

(Address of principal executive offices)

888-400-7179

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act(17CFR240.14a-12)

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act(17CFR240.14d-2(b))

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act(17CFR240.13e-4(c))

~~SAFE~~Section ~~HARBOR~~5 ~~STATEMENT~~- ~~UNDER~~Corporate ~~THE~~Governance ~~PRIVATE~~and ~~SECURITIES LITIGATION REFORM ACT OF 1995~~Management

~~Information~~ Item 5.02 Departure ~~included in this Form 8-K may contain forward-looking statements within the meaning~~ of ~~Section~~Directors 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). This information may involve known and unknown risks, uncertainties and other factors which may cause Capsalus Corp (“Capsalus”) and GeneWize Life Sciences, Inc. (“GeneWize”) actual results, performance or ~~achievements~~certain toofficers; beElection materially different from future results, performance or achievements expressed or implied by any forward-looking statements. Forward-looking statements, which involve assumptions and describe Capsalus and GeneWize future plans, strategies and expectations, are generally identifiable by use of ~~the~~Directors; ~~words~~Appointment ~~"may," "will," "should," "expect," "anticipate," "estimate," "believe," "intend" or "project" or the negative~~ of ~~these~~Certain ~~words~~Officers; orCompensatory ~~other~~Arrangements variations on these words or comparable terminology. Forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance that any projections or other expectations included in any forward-looking statements will come to pass. Capsalus and GeneWize’s actual results could differ materially from those expressed or implied by the forward-looking statements as a result of ~~various~~Certain ~~factors~~Officers. Except as required by applicable laws, Capsalus undertakes no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.

~~Item~~On 7September 21, 2011, the registrant accepted the resignation of Patrick G.~~01 Regulation~~ FDSheridan ~~Disclosure~~as Chief Financial Officer and Secretary of the registrant.

OnSteve ~~July~~M. 28Grubner, ~~2011,~~the ~~Capsalus~~registrant’s ~~issued~~President aand ~~press~~Chief ~~release~~Operating ~~related~~Officer tosince aJanuary ~~Letter~~2009, ofhas ~~Intent~~been ~~(“LOI”)~~appointed ~~signed with~~Interim ~~Genelink,~~Chief ~~Inc.,~~Financial toOfficer ~~acquire marketing rights~~ and ~~other~~Secretary. ~~assets~~Further ofinformation ~~GeneWize~~regarding ~~Life Sciences, Inc~~Mr., aGrubner ~~wholly~~and ~~owned~~his ~~direct~~background ~~selling~~and ~~subsidiary~~business ofexperience ~~GeneLink,~~can ~~Inc. Both~~be ~~parties~~found toin the ~~LOI~~registrant’s ~~are~~Form ~~conducting~~10-K ~~their~~filings ~~“due~~on ~~diligence”.~~both ~~There is no assurance that~~ the ~~acquisition~~Securities byand ~~Capsalus~~Exchange ofCommission’s ~~certain~~and ~~assets~~registrant’s ofwebsites. ~~GeneWize~~Mr. Sheridan will beremain ~~completed A~~a ~~copy~~consultant offor the ~~news~~registrant ~~release~~to ishelp ~~attached~~with asthe ~~Exhibit~~preparation ~~99.1~~of ~~hereto~~the ~~and~~registrant’s ~~incorporated~~third ~~herein~~quarter byForm ~~reference.~~10-Q ~~This~~and ~~disclosure~~year-end ~~does~~Form ~~not constitute an offer to sell, or the solicitation to buy, any such security~~10-K.

~~Item~~Section ~~9.01~~7 ~~Financial~~- ~~Statements~~Regulation ~~and Exhibits.~~FD

~~(d)~~Item ~~Exhibits~~7.01 Regulation ~~99.1~~FD ~~News Release dated July 28, 2011~~Disclosure.

A notice dated September 23, 2011, relating to the departure of Mr. Sheridan and the appointment of Mr. Grubner, which has been posted on the registrant’s website at www.capsalus.com, is attached to this Form 8-K as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits

	(d)	Exhibits.
		99.1 Notice dated September 23, 2011, posted on registrant’s website.

SIGNATURE

Pursuant to the Requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the Undersigned hereunto duly authorized.

	CAPSALUS CORP. (Registrant)
Date: July 29, 2011	By:	/s/ Steven M. Grubner
Date: September 23, 2011	By:	/s/ Steven M. Grubner
		Steven M. Grubner, Interim Chief Executive Officer

Filing Compare · FORU Holdings, Inc.